These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27811451)

  • 1. Expressions of macrophage migration inhibitory factor in patients with chronic kidney disease.
    Liu Y; Zhang X; Liu G; Huang J; Pan Y; Hu Z
    Niger J Clin Pract; 2016; 19(6):778-783. PubMed ID: 27811451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis.
    Luedike P; Rammos C; Pohl J; Heisler M; Totzeck M; Kleophas W; Hetzel GR; Kelm M; Hendgen-Cotta U; Rassaf T
    PLoS One; 2015; 10(10):e0140215. PubMed ID: 26485680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation.
    Eser B; Yayar O; Buyukbakkal M; Erdogan B; Ercan Z; Merhametsiz O; Haspulat A; Oğuz EG; Dogan İ; Canbakan B; Ayli MD
    Nefrologia; 2015; 35(5):465-72. PubMed ID: 26394828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum renalase in hemodialysis patients: is it related to left ventricular hypertrophy?
    Oguz EG; Gursoy GK; Yayar O; Yildirim T; Cimen T; Bulut C; Eser B; Canbakan B; Yeter E; Ayli MD
    Ren Fail; 2016 Sep; 38(8):1180-6. PubMed ID: 27416751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease.
    Rammos C; Hendgen-Cotta UB; Sobierajski J; Adamczyk S; Hetzel GR; Kleophas W; Dellanna F; Kelm M; Rassaf T
    Int J Cardiol; 2013 Oct; 168(6):5249-56. PubMed ID: 23978362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
    Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherosclerotic vascular disease is more prevalent among black ESKD patients on long-term CAPD in South Africa.
    Oguntola SO; Hassan MO; Duarte R; Vachiat A; Manga P; Naicker S
    BMC Nephrol; 2019 Oct; 20(1):399. PubMed ID: 31666030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease.
    Poulikakos D; Ross L; Recio-Mayoral A; Cole D; Andoh J; Chitalia N; Sharma R; Carlos Kaski J; Banerjee D
    Eur Heart J Cardiovasc Imaging; 2014 Jan; 15(1):56-61. PubMed ID: 23811493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.
    Unver S; Kavlak E; Gümüsel HK; Celikbilek F; Esertas K; Muftuoglu T; Kirilmaz A
    Ren Fail; 2015 Jul; 37(6):951-6. PubMed ID: 26030798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients.
    Karakan S; Sezer S; Özdemir Acar FN; Haberal M
    Ren Fail; 2012; 34(6):732-7. PubMed ID: 22503095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of left ventricular hypertrophy in Chinese hemodialysis patients is higher than that in peritoneal dialysis patients.
    Tian JP; Wang T; Wang H; Cheng LT; Tian XK; Lindholm B; Axelsson J; Du FH
    Ren Fail; 2008; 30(4):391-400. PubMed ID: 18569912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with reduction of left ventricular mass in children on peritoneal dialysis.
    Yu JJ; Jun HO; Shin EJ; Baek JS; Lee JH; Kim YH; Park YS; Ko JK
    Nephrology (Carlton); 2018 Apr; 23(4):338-344. PubMed ID: 28199756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients.
    Ayerden Ebinç F; Ebinç H; Derici U; Aral A; Aybay C; Taçoy G; Koç E; Mutluay R; Altok Reis K; Erten Y; Arinsoy T; Sindel S
    J Nephrol; 2009; 22(2):216-23. PubMed ID: 19384839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dialysis-related systemic microinflammation is associated with specific genomic patterns.
    Zaza G; Pontrelli P; Pertosa G; Granata S; Rossini M; Porreca S; Staal FJ; Gesualdo L; Grandaliano G; Schena FP
    Nephrol Dial Transplant; 2008 May; 23(5):1673-81. PubMed ID: 18048420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.
    Bruchfeld A; Carrero JJ; Qureshi AR; Lindholm B; Barany P; Heimburger O; Hu M; Lin X; Stenvinkel P; Miller EJ
    Mol Med; 2009; 15(3-4):70-5. PubMed ID: 19081768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis.
    Randon RB; Rohde LE; Comerlato L; Ribeiro JP; Manfro RC
    Braz J Med Biol Res; 2005 Sep; 38(9):1409-16. PubMed ID: 16138225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
    Stojimirović B; Petrović D; Obrenović R
    Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease.
    Zoccali C; Benedetto F; Mallamaci F; Tripepi G; Cutrupi S; Pizzini P; Malatino LS; Bonanno G; Seminara G
    J Hypertens; 2006 Oct; 24(10):2039-46. PubMed ID: 16957565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mitofilin in left ventricular hypertrophy in hemodialysis patients.
    Wu QS; He Q; He JQ; Chao J; Wang WY; Zhou Y; Lou JZ; Kong W; Chen JF
    Ren Fail; 2018 Nov; 40(1):252-258. PubMed ID: 29619900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 18 as a new inflammatory mediator in left ventricular hypertrophy in children with end-stage renal disease.
    Badawy A; Nigm DA; Ezzat GM; Gamal Y
    Saudi J Kidney Dis Transpl; 2020; 31(6):1206-1216. PubMed ID: 33565432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.